Medical News Today -- Prostate cancer in men usually becomes resistant to initial hormone treatment within a few years of diagnosis (and is thereafter called castration-resistant prostate cancer) and tumours begin to grow again and spread to other parts of the body (metastasis), including bones. This increases the risk of bone breakages and other bone events that cause significant disability and quality of life issues. An Article published Online First by The Lancet shows that a new drug denosumab is better than the current standard treatment of zoledronic acid for delaying and preventing bone events in men with castration-resistant prostate cancer. The Article is by Professor Karim Fizazi, Department of Cancer Medicine, University of Paris Sud, France, and colleagues.
